Neurological Sciences

, Volume 23, Issue 2, pp s83-s84

Amantadine in Huntington's disease: open-label video-blinded study

  • C. LucettiAffiliated withDepartment of Neuroscience, University of Pisa, Pisa, Italy
  • , G. GambacciniAffiliated withDepartment of Neuroscience, University of Pisa, Pisa, Italy
  • , S. BernardiniAffiliated withDepartment of Neuroscience, University of Pisa, Pisa, Italy
  • , G. Dell'AgnelloAffiliated withDepartment of Neuroscience, University of Pisa, Pisa, Italy
  • , L. PetrozziAffiliated withDepartment of Neuroscience, University of Pisa, Pisa, Italy
  • , G. RossiAffiliated withEpidemiology and Biostatistics Unit, Institute of Clinical Physiology, CNR, Pisa, Italy
  • , U. BonuccelliAffiliated withDepartment of Neuroscience, University of Pisa, Pisa, Italy

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Abstract.

Huntington's disease (HD) is characterized by chorea, cognitive and behavioral changes. Amantadine, a non-competitive NMDA receptor antagonist, has shown an antidyskinetic effect on levodopa-induced dyskinesias, which are known to have strict pathogenetic analogies with choreic hyperkinesias. The antidyskinetic efficacy of amantadine and its effects on cognitive and behavioural symptoms were evaluated. Eight HD patients received oral amantadine (100 mg tid) unblinded for a 1-year period. A significant reduction of dyskinesias was reported (p<0.01). No changes were observed in neuropsychologic and psychiatric assessments after 6 and 12 months of therapy. These data may have relevance to the treatment of HD with amantadine.